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61.5% specificity, p = 0.047). Histopathological non-
responders had a higher risk of death (HR 8.461, p = 0.001) 
and recurrence (HR 6.385, p = 0.002) and similarly in met-
abolic non-responders for death (HR 2.956, p = 0.063) and 
recurrence (HR 3.614, p = 0.028). Ordinalised ∆%SUVmax 
showed a predictive trend for OS and DFS, but failed to 
achieve statistical significance.
Conclusions PR was a stronger predictor of survival 
than metabolic response. ∆%SUVmax ≥70% was the 
best biomarker on PET that predicted PR and survival in 
oesophageal and gastric adenocarcinoma. Ordinalisation 
of ∆%SUVmax was not helpful in predicting primary 
outcomes.
Keywords Oesophageal cancer · Gastric cancer · 
Treatment response · FDG · PET · PET-CT
Introduction
Despite the increase in the incidence of oesophageal 
adenocarcinoma since 1988 and the steady decline in the 
incidence of gastric adenocarcinoma since 1982, oesoph-
ageal and gastric malignancies collectively accounted 
for 2317 deaths in Australia in 2010 [1]. While surgery 
remains the mainstay of curative treatment, the admin-
istration of neoadjuvant multimodality therapy has been 
shown to increase rates of histopathological complete 
response and entail modest survival benefit over sur-
gery alone [2]. Positron emission tomography (PET) 
using 18F-2-fluoro-2-deoxyglucose (18F-FDG) permits 
in  vivo characterisation of pathological 18F-FDG reten-
tion and PET has gained acceptance for initial staging of 
oesophageal malignancy by improving the detection of 
occult distant metastases [3]. Recently, several authors 
Abstract 
Background and objectives We retrospectively evaluated 
the value of PET/CT in predicting survival and histopatho-
logical tumour-response in patients with distal oesopha-
geal and gastric adenocarcinoma following neoadjuvant 
treatment.
Methods Twenty-one patients with resectable distal 
oesophageal adenocarcinoma and 14 with gastric adeno-
carcinoma between January 2002 and December 2011, 
who had undergone serial PET before and after neoadju-
vant therapy followed by surgery, were enrolled. Maximum 
standard uptake value (SUVmax) and metabolic tumour 
volume were measured and correlated with tumour regres-
sion grade and survival.
Results Histopathological tumour response (PR) is a 
stronger predictor of overall and disease-free survival 
compared to metabolic response. ∆%SUVmax ≥70% was 
the only PET metric that predicted PR (82.4% sensitivity, 
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have investigated the predictive value of PET metrics for 
early response to therapy in oesophageal and gastric neo-
plasms, given that PET has been shown to be useful in 
other cancers [4–7].
Tumour regression grades (TRG), a measure of histo-
pathological tumour response (PR) based on an estima-
tion of the percentage of residual tumour tissue in rela-
tion to the macroscopically identifiable tumour bed at 
the primary site, was adopted from studies conducted on 
gastric cancers [8] and oesophageal adenocarcinomas [9]. 
Lordick, et al. [10] validated the use of therapy-induced 
changes in PET metrics to predict PR and to stratify distal 
oesophageal and gastric cardia adenocarcinoma patients 
into different prognostic groups. They concluded that 
35% regression of maximum standardised uptake value 
 (SUVmax), a semi-quantitative measure of 18F-FDG reten-
tion in the primary tumour bed was the optimal cut-off 
to identify histopathological responders with 100% sensi-
tivity and 58% specificity. However, the evidence regard-
ing the predictive value of PET-based biomarkers in gas-
tric cancers is limited and inconsistent. One prospective 
study on advanced gastric cancer patients confirmed the 
highly predictive value of 35% reduction in  SUVmax on 
PR with 77% sensitivity and 86% specificity [11], while 
one small study comprising locally advanced gastric can-
cers showed a 45% decrease in SUV from baseline and 
day 35 significantly predicted PR whereas the change at 
day 15 did not [12].
There is increasing interest in investigating the prog-
nostic value of PET volumetric parameters such as meta-
bolic tumour volume (MTV), but the utility of this more 
novel imaging biomarker is experimental. One study 
reported that a 63% reduction in MTV was the optimal 
cut-off to identify histopathologically responding dis-
tal oesophageal adenocarcinoma with 91% sensitivity 
and 90% specificity [13]. The evidence on the predictive 
value of MTV in gastric cancer is scarce.
Several authors have validated that metabolic respond-
ers  (MR+) identified on PET had better prognosis [10, 11, 
14]. Some studies have shown variable thresholds [15] in 
predicting PR and survival on PET, while others failed 
to validate the predictive power of PET metrics [16, 
17]. Lee did not find a correlation between the change 
in  SUVmax of the primary tumour with PR after neoad-
juvant chemotherapy and surgery in gastric carcinoma 
[18]. Vallbohmer also did not find a correlation between 
a change in  SUVmax (baseline and post-treatment PET at 
2 weeks) and PR (<10% viable cells) or overall survival 
in oesophageal carcinoma [19]. This study aims to retro-
spectively evaluate the performance of PET in predict-
ing survival and PR to neoadjuvant therapy in patients 




Fifty-six patients with newly diagnosed resectable distal 
oesophageal and gastric adenocarcinoma who underwent 
neoadjuvant therapy and serial 18F-FDG PET scans at 
Liverpool Hospital (Sydney, Australia) between Janu-
ary 2002 and December 2011 were included. 35 patients 
(21 patients with distal oesophageal adenocarcinoma and 
14 patients with gastric adenocarcinoma) with sufficient 
PET data and TRG scores were analysed (Fig. 1). Patients 
with non-resectable disease at diagnosis, non-FDG-avid 
primary tumour on initial PET scan (PET-1), insufficient 
PET data, active concurrent cancer unrelated to oesopha-
geal and gastric cancer, previous neoadjuvant therapy 
prior to initial PET and those who did not undergo sur-
gery were excluded. Post-treatment PET (PET-2) param-
eters were not evaluated in one patient with a significant 
difference in uptake time between the two PET scans 
(64 min) and in five patients who had oesophageal stents 
implanted after PET-1. Most patients underwent PET/CT 
5 patients had stent; 1 had prolonged 
FDG uptake time difference
Abbreviations: PET, positron emission tomography; TRG, tumour regression grade; 
n, number of patients.
Resectable distal oesophageal and gastric 
adenocarcinoma who underwent neoadjuvant 
therapy and serial PET scans (n=56)
Sufficient PET data (n=46)
Surgery (n=41)
TRG scores available (n=35)
Baseline PET (n=35) and Post-treatment PET 
data (n=29)
Survival analysis and Histopathological 
tumour response evaluation
3 patients did not undergo surgery; 2 
patients had surgery aborted
TRG scores of 6 patients 
not retrievable
Fig. 1  Patient selection. PET positron emission tomography, TRG 
tumour regression grade, n number of patients
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scans apart from two patients where PET-alone imaging 
was performed.
Tumour staging was based on the sixth edition of the 
American Joint Committee of Cancer (AJCC) Staging 
Manual [20], but classification of tumour location was 
based on the seventh edition [21].
Patient information
Demographic, clinical and follow-up data were gathered 
through various databases including the South Western 
Sydney Area Health Service’s (SWSAHS) online patient 
information system, Cancer Therapy Centre (MOSAIQ), 
Departments of Surgery and Nuclear Medicine and PET.
PET imaging
All patients underwent a baseline PET scan for staging 
(PET-1) and a post-treatment PET scan (PET-2). PET-
alone scans operating in three-dimensional mode (Allegro, 
Philips Medical Systems, Milpitas, CA, US) with germa-
nium source attenuation were performed prior to February 
2006, and PET/CT scans (Gemini GXL-6, Philips Medical 
Systems, Miltipas, CA, US) using low-dose CT without 
contrast enhancement for attenuation correction.
A standardised protocol comprised a minimum 4-h fast-
ing period and blood glucose levels <10  mmol/L prior to 
18F-FDG (5.14  MBq/kg), administration intravenously. 
Patients were scanned after an uptake period of approxi-
mately 60 min.
PET data analysis
PET scans were analysed by two accredited Nuclear Medi-
cine physicians in consensus (M.L. and J.Y.) according to 
a standardised protocol where the  SUVmax was measured 
using a 15 mm wide region of interest around the primary 
tumour. MTV was measured using vendor’s software with 
a  SUVmax threshold that best delineated the tumour. Scans 
(PET-1 and PET-2) were analysed blinded from all clinical, 
pathological and imaging data apart from the knowledge 
that all patients had oesophageal and gastric malignancy 
and had completed neoadjuvant therapy. PET-1 and PET-2 
measurements and any absolute and relative differences in 
18F-FDG uptake were correlated with TRG and survival. 
If no residual tumour was visible and uptake was indistin-
guishable from background oesophageal or gastric activity 
on post-treatment scan, no volumetric measurement was 
attempted and the percentage reduction in abnormal tracer 
uptake is assigned 100%. Metabolic responders  (MR+) are 
patients with ∆%SUVmax ≥70%.
Histopathological response evaluation
Surgical specimens were retrospectively examined by a 
single pathologist (S.L.). TRG score was assessed semi-
quantitatively into either complete (TRG 1a: no residual 
tumour), subtotal (TRG 1b: <10% of residual tumour), 
partial (TRG 2: 10–50% of residual tumour) and minimal 
response (TRG 3: >50% residual tumour) based on Becker 
et  al. [8]. The pathologist was blinded from all clinical, 
pathological and imaging data. Patients with complete or 
subtotal tumour regression were classified as histopatho-
logical responders  (PR+). All other patients were classified 
as non-responders  (PR−).
Follow‑up
Disease-status and survival status at the time of census 
were recorded. Overall survival (OS) was calculated from 
the date of PET-1 to date of death or date of most recent 
follow-up. Disease-free survival (DFS) was calculated from 
date of surgery to the date of confirmed recurrence. If death 
was a direct consequence of surgery within 2 weeks of sur-
gery, then the patient was excluded from survival analyses.
Statistical analysis
Absolute numbers and percentages were computed to 
describe the patient population, and quantitative values 
are expressed as median and range. Chi-square test was 
used to examine associations between categorical vari-
ables. Receiver operator characteristics (ROC) curve was 
performed to find the optimal cut-offs of the PET param-
eters. Survival curves were generated using Kaplan–Meier 
estimates and significance of difference between curves 
was tested with log-rank tests. Univariate analysis of sur-
vival was performed using Cox regression analysis and the 
estimated hazard ratio (HR) and 95% confidence interval 
(CI) were reported. All statistical analyses were performed 




There was a preponderance of male subjects and neoadju-
vant chemotherapy-alone treatment in the cohort (Table 1). 
Most patients were node negative on staging PET.
There was a significant difference (p = 0.002) in the 
median patient weight at PET-1 (79 kg, 48–115) compared 
to PET-2 of (76 kg, 55–118). Median uptake time at PET-1 
was 63 min and for PET-2 was 64 min (p = 0.878) with a 
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median difference in uptake times of 6  min (0–22). The 
median interval between the two PET scans was 106 days 
(55–153).
PET and histopathological tumour response evaluation
The relative reduction in  SUVmax (∆%SUVmax) ≥70% 
was the only optimum cut-off to predict PR (p = 0.047) on 
ROC analysis with 82.4% sensitivity and 61.5% specific-
ity. There was a trend for a greater proportion of  PR+ hav-
ing an absolute reduction in  SUVmax (∆SUVmax) ≥5.75 
(p = 0.071). Other PET metrics did not retain statistical sig-
nificance and were dichotomised at the respective median 
values (Table 2). By ordinalising ∆%SUVmax into a schema 
similar to that of TRG with complete response (∆%SUV-
max  =  100%), subtotal response (∆%SUVmax  ≥70%), par-
tial response (∆%SUVmax  ≥35%) and minimal response 
(∆%SUVmax <35%), no significant result was attained.
PET, TRG and survival analysis
MR+ and  PR+ had a significantly longer OS and DFS than 
their non-responding counterparts (Fig. 2). Median OS and 
DFS were not reached in  MR+.
PR− had a significantly greater risk of death (HR 8.461; 
p = 0.001) and recurrence (HR 6.385; p = 0.002) (Table 3). 
Similarly, metabolic non-responders  (MR−) with ∆%SUV-
max <70% entailed a significantly greater risk of death (HR 
2.956, p = 0.063) and recurrence (HR 3.614; p = 0.028) 
(Table  3). PR was a stronger predictor of OS (HR 8.461 
vs 2.956) and DFS (HR 6.385 vs 3.614) compared to 
∆%SUVmax≥70%.
For PET-1, baseline  SUVmax <9.70 was the only sta-
tistically significant predictor of poor OS (HR 2.589, 
p = 0.044). The ∆%SUVmax <70% cut-off showed a trend 
(p = 0.063) towards poorer OS. Both groups reported a 
higher risk of recurrence (p = 0.030; p = 0.028) (Table  3). 
All other PET metrics were not statistically significant.
When we analysed TRG as a binary parameter-complete 
or subtotal (TRG 1a and TRG 1b), and partial or minimal 
Table 1  Patient characteristics and clinicopathological parameters
T stage, depth of invasion, N stage nodal involvement, PET positron 
emission tomography, AJCC American Joint Committee of Cancer 
Staging Manual, N− negative nodal involvement, N+ positive nodal 
involvement; CT chemotherapy, CRT chemoradiotherapy, RT radio-





Median age at diagnosis 61.7 years (40.6–74.5)
Histology
 Signet ring cell 4 (11.4)
 Non-Signet ring cell 31 (88.6)
Tumour Location (AJCC 7th ed.)
 Distal oesophagus 18 (51.4)
 Stomach 17 (48.6)
  Cardia of stomach 9
  Fundus 1











Nodal involvement on staging PET
 N− 26 (74.3)
 N+ 9 (25.7)





Type of neoadjuvant therapy
 CT alone 20 (57.1)
 CRT 9 (25.7)
 RT alone 3 (8.6)














Median overall survival 22.3 months (9.6-122.4)
Median follow-up period 22.7 months (10.8-122.4)
Two-year overall survival rate 40.0%
Table 1  continued
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response (TRG 2 and 3), TRG was significantly associated 
with survival status (p = 0.002) on Chi-square analysis.
Discussion
The correlations between TRG, survival and PET-metrics 
have not been widely reported in oesophageal and gastric 
adenocarcinomas. This study comprised a heterogene-
ous group with resectable adenocarcinoma of the distal 
oesophagus and stomach. Although surgical treatment of 
oesophageal and gastric cancers occurs in relatively low 
volume centres in Australia, we have equivalent short and 
long term outcomes compared to Asian and European insti-
tutions [22, 23]. Therefore, our findings on the predictive 
performance of PET for survival and PR in this group are 
applicable to other populations. The study is also strength-
ened with centralized PET scan interpretation in consensus.
We found that a favourable metabolic response is asso-
ciated with favourable PR. A reduction of  SUVmax of the 
primary ≥70% following neoadjuvant treatment was associ-
ated with a  TRG1a–1b. Our study showed that ∆%SUVmax 
≥70% (p = 0.047) was the optimal cut-off that characterised 
PR with 82.4% sensitivity and 61.5% specificity. To our 
knowledge, the association between PR and PET metrics 
have not been studied extensively in gastric cancers. This 
is in line with a small study of 35 patients using PET-alone 
system which demonstrated ∆%SUVmax  ≥35% predicted 
survival in locally advanced gastric cancer [11]. Our data 
included only two patients who underwent PET-alone 
imaging and while we acknowledge PET-alone and PET-
CT can produce differences in SUV due to different meth-
ods of attenuation correction, the difference is reported to 
be relatively small in the clinical setting for non-osseous 
lesions of a sufficient size (our cohort comprised mostly T3 
or T4 tumours) [24, 25].
Although there was a trend for an absolute therapy-
induced change in  SUVmax (p = 0.07) in predicting PR, 
we showed relative reduction as a stronger predictor. This 
may be due to the variable physiologic background FDG 
uptake in the oesophagus and stomach and relative reduc-
tion appears to be a better metric to gauge response. There 
is currently no consensus on the optimal thresholds in 
determining metabolic response on PET and various inves-
tigators have found different cut-offs [10, 17, 26, 27]. This 
most likely reflects different camera specifications and 
methodology and a standardised protocol in future prospec-
tive trials is mandatory [28].
There are conflicting results regarding the use of PET 
metrics in predicting survival in gastric cancer [29–31]. 
Our results demonstrated both  MR+ and  PR+ had signifi-
cantly longer OS and DFS than non-responders (Fig.  2). 
Becker et  al. [8] showed that  PR+ (TRG 1a/1b) in 480 
gastric adenocarcinoma patients had a significantly longer 
OS (128.6 months) compared to partial (61.9 months) and 
minimal (40.1 months) responders and similar conclusions 
were drawn from studies on distal oesophageal adenocarci-
noma [9]. In our study,  MR+ had a significantly longer OS 
(median NR vs 23.5 months) and longer DFS (median NR 
Table 2  Predictive value of various PET parameters of tumour 
regression grade (TRG) score
Statistical significant result is in bold
Post-treatment scans in 5 patients were excluded from analysis due to 
oesophageal stent insertion. One patient was excluded due to signifi-
cant difference in uptake times between the two scans
 PET positron emission tomography, TRG tumour regression grade, 
SUV1max baseline  SUVmax, SUV2max post-treatment  SUVmax, ∆SUV-
max absolute reduction in  SUVmax, ∆%SUVmax relative reduction in 
 SUVmax, MTV metabolic tumour volume, MTV1 baseline MTV, 
MTV2 post-treatment MTV, ∆MTV absolute reduction in MTV, 
∆%MTV relative reduction in MTV
n (%) Chi-square p
TRG1a–1b TRG2–3
Baseline  SUVmax
 SUV1max ≥9.70 10 (28.6) 10 (28.6) 0.345 0.557
 SUV1max <9.70 6 (17.1) 9 (25.7)
Post-treatment  SUVmax
 SUV2max ≥3.75 5 (17.2) 8 (27.6) 0.386 0.534
 SUV2max <3.75 8 (27.6) 8 (27.6)
Metabolic response based on ∆SUVmax
 ∆SUVmax ≥5.75 10 (34.5) 7 (24.2) 3.254 0.071
 ∆SUVmax <5.75 3 (10.3) 9 (31.0)
Metabolic response based on ROC analysis of ∆%SUVmax
 ∆%SUVmax ≥70% 8 (27.6) 4 (13.8) 3.948 0.047
 ∆%SUVmax <70% 5 (17.2) 12 (41.4)
Baseline MTV (cm3)
 MTV1 ≥47.30 8 (27.6) 10 (34.5) 0.024 1.000
 MTV1 <47.30 8 (27.6) 9 (31.0)
Post-treatment MTV (cm3)
 MTV2 ≥12.00 3 (11.0) 7 (22.8) 1.008 0.315
 MTV2 <12.00 8 (27.6) 8 (27.6)
 Missing 3 (11.0)
Metabolic response based on ∆MTV
 ∆MTV ≥39.40 7 (22.8) 9 (31.0) 0.035 0.851
 ∆MTV <39.40 4 (13.2) 6 (22.0)
 Missing 3 (11.0)
Metabolic response based on ∆% MTV
 ∆%MTV ≥80% 5 (14.0) 6 (22.0) 0.077 0.781
 ∆%MTV <80% 6 (22.0) 9 (31.0)
 Missing 3 (11.0)
Metabolic response based on various cut-offs of ∆%SUVmax
 ∆%SUVmax = 100% 2 (6.9) 2 (6.9) 3.883 0.274
 ∆%SUVmax ≥70–99% 6 (20.7) 2 (6.9)
 ∆%SUVmax ≥35–69% 5 (17.2) 9 (31.1)
 ∆%SUVmax <35% 0 (0.0) 3 (10.3)
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vs 16.5 months). These findings are similar to those from 
the MUNICON I trial [10]. There was a trend for  MR− to 
have an almost threefold increase in risk of death (p = 0.06) 
and a significantly shorter DFS (p = 0.028) (Table  3). 
Although high  SUVmax in many tumours have been shown 
to be poor prognosticators [32], in our study a high baseline 
 SUVmax (>9.7) did not predict poor OS. This observation 
has also been shown in one study where patients with meta-
static disease had lower  SUVmax and  SUVmean compared 
to M0 patients [33] and in another, no significant differ-
ence was found between limited and disseminated gastric 
cancers [34]. This may be due to several poor prognostic 
histological sub-types having low glucose metabolism, 
e.g. signet-ring cell or mucinous adenocarcinoma. Recent 
evidence also suggests a relationship between FDG avidity 
and HER2 expression and PET may have the potential to 
predict tumour phenotype [35].
PR+ in our study had a greater reduction in tumour 18F-
FDG metabolism, highlighting the potential to formulate 
PET-guided treatment algorithm, which has been validated 
in the MUNICON II trial [36]. The greater histopathologi-
cal remission rate among  MR− of the MUNICON II trial 
compared to those in the MUNICON I trial was attributed 
to the PET-based early metabolic assessment and subse-
quent escalation of therapy in  MR− from chemotherapy-
alone to chemoradiotherapy [10, 36].  MR− in the MUNI-
CON I trial had their chemotherapy stopped after 2 weeks 
and went directly to surgical resection potentially avoiding 
toxicity from futile chemotherapy. Despite the addition of 
radiotherapy to cisplatin or 5-fluorouracil based chemother-
apy in MUNICON II trial,  MR− still had a poor prognosis. 
A recent trial comprising a small number of patients sug-
gested that changing chemotherapy regimens (to taxane-
based) in PET non-responding patients may improve out-
comes [37].
Fig. 2  Kaplan–Meier Analysis. PR and OS (a), PR and DFS (b), MR and OS (c), MR and DFS (d). PR histopathological tumour response, MR 
metabolic tumour response on PET, OS overall survival, DFS disease-free
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To our knowledge, this is the first study to ordinalise 
∆%SUVmax similar to TRG scores using ∆%SUVmax ≥70% 
and ∆%SUVmax  ≥35% cut-offs. Although it failed to 
achieve statistical significance, our analysis showed a pre-
dictive trend for DFS and OS (Table 3). This warrants fur-
ther investigation in a larger cohort.
Volumetric measurements on PET is emerging as an 
important novel imaging biomarker in predicting progno-
sis in non-small cell lung (NSCLC) [7] and oesophageal 
cancers [13, 38], but there is limited evidence in gastric 
malignancies. In our study, neither the median MTV nor 
the MTV determined by ROC analysis (data not shown) 
Table 3  Prognostic value of 
metabolic parameters on PET 
and histopathological tumour 
response for survival
Statistical significant result is in bold
Post-treatment scans in five patients were excluded from analysis due to oesophageal stent insertion. One 
patient was excluded due to significant difference in uptake times between the two scans
 PET positron emission tomography, OS overall survival, DFS Disease-free survival, HR Hazard ratio, CI 
confidence interval, n number of patients, SUV1max baseline  SUVmax, SUV2max post-treatment  SUVmax, 
∆SUVmax absolute reduction in  SUVmax, ∆%SUVmax relative reduction in  SUVmax, MTV metabolic tumour 
volume, MTV1 Baseline MTV, MTV2 post-treatment MTV, ∆MTV absolute reduction in MTV, ∆%MTV 
relative reduction in MTV, TRG tumour regression grade
n (%) Univariate Cox regression test Univariate Cox regression test
OS HR 95% CI p DFS HR 95% CI p
Baseline  SUVmax
 SUV1max ≥9.70 20 (57.1) 1.000 0.044 1.000 0.030
 SUV1max < 9.70 15 (42.9) 2.589 1.025–6.535 2.797 1.107–7.071
Post-treatment  SUVmax
 SUV2max ≥3.75 13 (44.8) 1.000 0.376 1.000 0.352
 SUV2max < 3.75 16 (55.2) 1.627 0.554–4.780 1.658 0.572–4.812
Metabolic response based on ∆SUVmax
 ∆SUVmax ≥ 5.75 17 (58.6) 1.000 0.112 1.000 0.066
 ∆SUVmax < 5.75 12 (41.2) 2.223 0.829–6.013 2.563 0.941–6.981
Metabolic response based on ROC analysis of ∆%SUVmax
 ∆%SUVmax ≥70% 12 (41.2) 1.000 0.063 1.000 0.028
 ∆%SUVmax <70% 17 (58.6) 2.956 0.945–9.247 3.614 1.150–11.533
Baseline MTV  (cm3)
 MTV1 ≥47.30 18 (51.4) 1.000 0.141 1.000 0.133
 MTV1 < 47.30 17 (48.6) 1.996 0.795–5.013 2.031 0.806–5.118
Post-treatment MTV  (cm3)
 MTV2 ≥12.00 10 (34.5) 1.000 0.817 1.000 0.795
 MTV2 < 12.00 16 (55.2) 0.860 0.241–3.074 0.845 0.238–3.003
 Missing 3 (10.3)
Metabolic response based on ∆MTV
 ∆MTV ≥39.40 16 (55.2) 1.000 0.305 1.000 0. 362
 ∆MTV < 39.40 10 (34.5) 1.182 0.583–5.639 1.698 0.544–5.296
 Missing 3 (10.3)
Metabolic response based on ∆% MTV
 ∆%MTV ≥80% 10 (34.5) 1.000 0.707 1.000 0. 681
 ∆%MTV < 80% 16 (55.2) 0.792 0.235–2.672 0.775 0.231–2.605
 Missing 3 (10.3)
Metabolic response based on various cut-offs of ∆%SUVmax
 ∆%SUVmax = 100% 4 (13.8) 1.000 1.000
 ∆%SUVmax ≥70–99% 8 (27.6) 0.402 0.056–2.898 0.366 0.454 0.063–3.247 0.431
 ∆%SUVmax ≥35–69% 14 (48.3) 1.552 0.331–7.727 0.577 2.137 0.460–9.922 0.332
 ∆%SUVmax <35% 3 (10.3) 3.241 0.429–24.495 0.254 3.718 0.491–28.183 0.204
Histopathological tumour response
 TRG1a–1b 16 (45.7) 1.000 1.000
 TRG2–3 19 (54.3) 8.461 2.355–30.396 0.001 6.385 2.019–20.195 0.002
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predicted PR and survival, perhaps due to the difficulty and 
inaccuracy in delineating MTV using different SUV thresh-
olds. This may partly be due to the variable physiological 
18F-FDG uptake in gastric mucosa which attenuates the 
tumour to background ratio. Hence, MTV may not have 
the same prognostic value in gastric cancer compared with 
NSCLC or oesophageal cancer.
This retrospective study comprised only FDG-avid gas-
tric tumours. It is well known that a significant proportion 
of gastric cancers can be falsely negative on FDG PET 
in particular in tumours rich in mucin and our data is not 
applicable to all gastric cancers [39–41]. We combined 
patients with distal oesophageal and gastric cancers due 
to small sample size and a larger population could have 
allowed subgroup analyses.
In conclusion, PR was a stronger prognostic indica-
tor than metabolic response, and ∆%SUVmax was the best 
PET-based biomarker that predicted PR and survival in 
oesophageal and gastric adenocarcinoma. This study high-
lighted the potential role of PET in optimising treatment 
protocols and allows non-responders to be detected early to 
have escalation of treatment in this poor prognostic group.
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